Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raludotatug Deruxtecan in Advanced Ovarian Cancer (REJOICE-Ovarian02)
NCT06843447Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2025
- Primary completion
- Mar 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of raludotatug deruxtecan in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by Merck & Co.. Started Apr 2025; status: recruiting.
02
Drugs
raludotatug deruxtecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT06843447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06843447.